Technology
Health
Biotechnology

Arbutus Biopharma

$1.91
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.09 (-4.50%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell ABUS and other stocks, options, ETFs, and crypto commission-free!

About

Arbutus Biopharma Corp. engages in discovering, developing and commercializing a cure for patients suffering from chronic Hepatitis B virus infection. The company was founded on October 6, 2005 and is headquartered in Burnaby, Canada.

Employees
80
Headquarters
Burnaby, British Columbia
Founded
2005
Market Cap
107.45M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
357.79K
High Today
$2.02
Low Today
$1.90
Open Price
$2.00
Volume
132.70K
52 Week High
$12.60
52 Week Low
$1.90

Collections

Technology
Health
Biotechnology
2015 IPO
Canada
North America

News

Yahoo FinanceMay 13

Arbutus to Present at Upcoming May 2019 Conferences

WARMINSTER, Pa., May 13, 2019 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that Dr. Mark J. Murray, Arbutus’ President and CEO, will present at the following conferences in May 2019: UBS Global Healthcare Conference – New York Monday, May 20, 2019, 1:00 PM ET RBC Capital Markets Healthcare Conference – New York Tuesday, May 21, 2019, 11:00 AM ET Live webcasts of the presentations can be accessed thr...

57
Seeking AlphaMay 6

Arbutus Biopharma Corporation (ABUS) CEO Mark Murray on Q1 2019 Results - Earnings Call Transcript

Arbutus Biopharma Corporation (NASDAQ:ABUS) Q1 2019 Results Earnings Conference Call May 6, 2019 4:30 PM ET Company Participants Pam Murphy - IR Mark Murray - CEO Mike Sofia - Chief Scientific Officer Gaston Picchio - Chief Development Officer Dave Hastings - CFO Conference Call Participants Keay Nakae - Chardan Mayank Mamtani - B Riley FBR Operator Good day, ladies and gentlemen, and welcome to the Arbutus Biopharma Corporation 2019 First Quarter Financial Results and Corporate Update Conference...

63
Associated PressMay 6

Arbutus Reports First Quarter 2019 Financial Results and Provides Corporate Update

10

Earnings

-$0.47
-$0.37
-$0.27
-$0.17
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 1, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.